DOCSLIB.ORG

Download Leaflet View the Patient Leaflet in PDF Format

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Download Leaflet View the Patient Leaflet in PDF Format NOT FINAL Q if you feel unable to stop smoking completely, or wish to Benefits you can get from using NRT instead of smoking Q if you are in hospital because of heart disease to your doctor, nurse or pharmacist for advice. i How to apply the patch 3 The patch should then be disposed of carefully in the quit smoking and want to stop using NICORETTE® invisi increase the time to your next cigarette with the intention For the best effect, ensure that you use NICORETTE® invisi (including heart attack, disorders of heart rate or rhythm, Products that are used intermittently may be preferable to 1 Wash your hands before applying the household rubbish, out of reach of children and animals. patch but are finding this difficult you should contact your of cutting down the number of cigarettes you smoke, angina, high blood pressure or stroke). nicotine patches. However, patches may be more suitable if doctor, nurse or pharmacist for advice. patch correctly – see ”How and when to use this medicine” patch. i When to use nicorette® invisi patch Q at those times when you can’t or do not want to smoke. The benefits of stopping smoking far outweigh any In other heart conditions not requiring you to be in you have nausea or sickness. If you do use patches take Below is the dosage information for NICORETTE® invisi For example, potential risk from using nicotine from NRT. It is the hospital, using NRT is better than continuing to smoke. them off before going to bed at night. If you are able to stop smoking immediately you should use patch. This shows the number of patches you should be invisi patch ® - where you don’t want to smoke and avoid harm to toxins in cigarette smoke such as tar, lead, cyanide and Q if you have stomach ulcers or oesophagitis If you are breast-feeding: 2 Each NICORETTE® invisi patch NICORETTE invisi patch, when needed, in place of using, when you should use them and where applicable the nicotine others e.g children or family ammonia that cause smoking related disease and (inflammation of the food pipe). 1) Firstly, you should try to give up smoking without NRT. comes in a child resistant sachet cigarettes by following the dosing instructions detailed maximum amount of time you should be using Nicotine transdermal patch - for prolonged periods (greater than 16 hours) where death, not the nicotine. Q if you are to undergo an MRI procedure. 2) Secondly, if you can’t manage this you are best to which can be opened by cutting along under section “Stopping Immediately”. Replacement Therapy (NRT) for. smoking cigarettes is not allowed e.g aeroplanes, Q if you have liver or kidney disease. If you are unable to stop smoking or do not feel ready to quit What should you know about Q You may think that smoking helps relieve feelings of use NRT products that are taken intermittently (not the edge with a pair of scissors. Please read this information carefully and then go to the work, social occasions Q if you have an overactive thyroid gland or have a patches), however you should talk to your doctor, nurse at this time, you should replace as many cigarettes as anxiety and stress, but it does not deal with the cause of phaeochromocytoma (a tumour of the adrenal gland that ® “How to stop smoking your choice” section which shows NICORETTE® NICORETTE® NICORETTE® It may also help increase your motivation to quit. the stress and leads to a number of serious diseases. In or pharmacist for advice. Breast-feed just before you use 3 Remove the patch from its sachet and possible with NICORETTE invisi patch. There are toxins in you how to give up. can affect blood pressure) – your doctor will have told NICORETTE® invisi patch to ensure that the baby gets cigarettes that can cause harm to your body. NICORETTE® invisi 25 mg invisi 15 mg invisi 10 mg When making a quit attempt a behavioural support addition, the feeling of relaxation after smoking is temporary, you this. then peel one part of the silvery aluminium Q Depending on where you are in your treatment the smallest amount of nicotine possible. backing away. Avoid touching the invisi patch provides a safer alternative to smoking, for both patch patch patch programme will increase your chances of success. with withdrawal symptoms and cravings soon returning. Q if you have diabetes – monitor your blood sugar levels programme, the strength of the patch that you are using ® sticky surface of the patch with your you and those around you. Reducing the amount of Step 1 Step 2 Step 3 nicorette® invisi 25 mg patch: Each patch releases NRT can help relieve nicotine withdrawal symptoms more often when starting to use NICORETTE invisi If you do need to use NRT to help you quit, the amount of may differ. See the “How to stop smoking your choice” such as irritability, low mood, anxiety, restlessness fingers. cigarettes may also help you to become more motivated to for more information. 25 milligrams of nicotine, the active ingredient, over 16 hours. patch as you may find your insulin or medication nicotine that the baby may receive is considerably smaller stop smoking. As soon as you are ready you should aim to Please read this leaflet carefully before you start using and cravings when used in place of cigarettes. requirements alter. and less harmful than the second-hand smoke they would Q However all patches are used and applied in the same way. ® stop smoking completely. nicorette invisi 15 mg patch: Each patch releases Q NRT may benefit 4 Carefully apply the sticky part of the this medicine. It provides useful information on how to use it smokers who want to quit, by helping Q if you have a skin disorder such as psoriasis, eczema inhale if you smoked. Tobacco smoke produces breathing i How to stop smoking - your choice safely. Keep the leaflet, you might need it again. 15 milligrams of nicotine, the active ingredient, over 16 hours. to control weight gain that may be experienced when or hives (urticaria) covering a large area of your skin. and other problems in babies and children. patch to the chosen area of skin and If you are planning to stop smoking or reduce the number of then peel off the remaining half of the cigarettes you smoke, NICORETTE® invisi patch can be Because smoking is an addiction you may find it difficult to If you think you are having side-effects, have any questions nicorette® invisi 10 mg patch: Each patch releases trying to stop smoking. Q if you are taking any other medicines such as theophylline, clozapine or ropinirole. Stopping smoking or 3 How and when to use this medicine silvery aluminium backing foil. used while you are still smoking. However, during this time, give up. From time to time you may still have strong urges to or are not sure about anything please ask your doctor, 10 milligrams of nicotine, the active ingredient, over 16 hours. Use of NRT is safer than smoking tobacco but as soon as smoke but if you follow these recommendations, you have a cutting down may require the dose of these medicines to ® you should aim to replace as many cigarettes as possible nurse or pharmacist. ® you are ready, you should aim to stop smoking completely. How to use nicorette invisi patch ® What does nicorette invisi patch do? be adjusted. 5 Press the patch firmly onto the skin with with NICORETTE invisi patch. As soon as you feel ready good chance of quitting. i Follow the instructions below. ® 1 What this medicine is for When you stop smoking or cut down the number of 2 Before using this medicine Q if you have ever experienced seizures (fits) your palm or finger tips. you should stop smoking completely. Follow the dosing If you find it hard to stop smoking using NICORETTE ® ³ If any of these apply, talk to your doctor, nurse instructions detailed under section “Stopping Gradually”. invisi patch, you are worried that you will start smoking NICORETTE invisi patch is a nicotine replacement cigarettes you smoke, your body misses the nicotine that X ® Choosing where to apply the patch Do not use nicorette invisi patch: 6 Run your fingers around the edge to ® again without it, or you find it difficult to reduce the number therapy (NRT). you have been absorbing. You may experience unpleasant or pharmacist. 1 Before applying your NICORETTE® invisi patch, choose You can also use NICORETTE invisi patch on those It is used to relieve and /or prevent Q if you have an allergy to nicotine or any of the other ensure it sticks firmly. of patches you are using, talk to your doctor, nurse or withdrawal symptoms and reduce the cravings you get feelings and a strong desire to smoke (craving). This ! If you are pregnant or breast-feeding a completely clean, dry area of hairless skin on the front occasions when you can’t or don’t want to smoke e.g. long indicates that you were dependent on nicotine. ingredients. i haul flights, social situations, or when at work. However, in pharmacist. when you try to stop smoking or when cutting down the Q If you are a child under 12 years of age. If you are pregnant: or side of the chest, upper arm or hip. Removing and disposing of the patch ® 2 Avoid placing the patch onto any area of skin that is red, smoke free areas such as pub, work breaks, public trans- i number of cigarettes you smoke.
Load more

Recommended publications
  • Formulation and Evaluation of Transdermal Patch and Gel of Nateglinide
    Human Journals Research Article September 2015 Vol.:4, Issue:2 © All rights are reserved by C. Aparna et al. Formulation and Evaluation of Transdermal Patch and Gel of Nateglinide Keywords: Nateglinide, transdermal patch and gel, HPMC, ethyl cellulose, carbopol, PVA, PVP ABSTRACT Anusha Gundeti, C. Aparna*, Dr. Prathima Srinivas The objective of the present work was to formulate Transdermal Drug Delivery systems of Nateglinide, an Department of Pharmaceutics, Sri Venkateshwara antidiabetic drug belonging to meglitinide class with a half life of 1.5 hrs. Transdermal patches containing nateglinide were College of Pharmacy, prepared by solvent casting method using the combinations Affiliated to Osmania University, of HPMC:EC, PVA:PVP, HPMC:Eudragit RS 100, Eudragit RL100:RS100 in different proportions and by incorporating Madhapur, Hyderabad, Telangana -500081, India. different permeation enhancers (polyethylene glycol 400, Su bmission: 7 September 2015 DMSO). The transdermal patches were evaluated for their physicochemical properties like thickness, weight variation, Accepted: 11 September 2015 folding endurance, percentage moisture absorption, percentage Published: 25 September 2015 moisture loss, in-vitro diffusion studies & ex-vivo permeation studies. Transdermal Gel was formulated using HPMC, carbopol 934, carbopol 940 and methyl cellulose. Gels were evaluated for homogeneity, pH, viscosity, drug content, in-vitro diffusion studies & ex-vivo permeation studies. By comparing the drug release F5 (HPMC:EC) formulation was selected as optimized formulation as it could sustain the drug release for 12 hrs i.e. 99.2% when compared to gel. Stability studies were www.ijppr.humanjournals.com carried out according to ICH guidelines and the patches maintained integrity and good physicochemical properties during the study period.
    [Show full text]
  • HEALTH PROFESSIONAL CONSULTANT to a PHARMACEUTICAL COMPANY V JOHNSON & JOHNSON Nicorette Advertisement
    CASE AUTH/2930/1/17 HEALTH PROFESSIONAL CONSULTANT TO A PHARMACEUTICAL COMPANY v JOHNSON & JOHNSON Nicorette advertisement A complaint was received in a private capacity that the implication was that the statement in from a health professional who stated that he/ question related to a feature of Nicorette, that the she worked as a consultant to a pharmaceutical product itself had incredible features and/or that company. health professionals would be doing something incredible by prescribing it. The implication was The complaint concerned an online advertisement misleading and exaggerated and breaches of the for Nicorette (nicotine) issued by Johnson & Code ruled. Johnson published in Pulse. The complainant stated at the time of submitting The complainant provided a screenshot of a the complaint that he/she was a health professional banner advertisement. It included ‘Nicorette. Do who worked as a consultant to Novartis. It had something incredible’. The complainant did not previously been decided, following consideration believe that the word ‘incredible’ was suitable. This by the then Code of Practice Committee and the information did not appear to be balanced and was ABPI Board of Management, that private complaints exaggerated. The claim was taken directly from from pharmaceutical company employees had material aimed at the general public and it appeared to be accepted. To avoid this becoming a means that Johnson & Johnson had not undertaken a of circumventing the normal procedures for sufficiently robust review when translating to intercompany complaints, the employing company promotion aimed at health professionals. would be named in the report. The complainant would be advised that this would happen and be The detailed response from Johnson & Johnson is given an opportunity to withdraw the complaint.
    [Show full text]
  • An Archetype Swing in Transdermal Drug Delivery
    Indo American Journal of Pharmaceutical Research, 2017 ISSN NO: 2231-6876 A COMPREHENSIVE REVIEW ON MICRONEEDLES - AN ARCHETYPE SWING IN TRANSDERMAL DRUG DELIVERY G. Ravi*, N. Vishal Gupta, M. P. Gowrav Department of Pharmaceutics, JSS College of Pharmacy, JSS University, Shri Shivarathreeshwara Nagara, Mysuru, Karnataka, India. ARTICLE INFO ABSTRACT Article history Transdermal drug delivery is the non-invasive delivery of medications through the skin Received 23/12/2016 surface into the systemic circulation. The advantage of transdermal drug delivery system is Available online that it is painless technique of administration of drugs. The advantage of transdermal drug 31/01/2017 delivery system is that it is painless technique of administration of drugs. Transdermal drug delivery system can improve the therapeutic efficacy and safety of the drugs because drug Keywords delivered through the skin at a predetermined and controlled rate. Due to the various Microneedles, biomedical benefits, it has attracted many researches. The barrier nature of stratumcorneum Hypodermic Needles, poses a danger to the drug delivery. By using microneedles, a pathway into the human body Transdermal, can be recognized which allow transportation of macromolecular drugs such as insulin or Stratumcorneum, vaccine. These microneedles only penetrate outer layers of the skin, exterior sufficient not to Patch. reach the nerve receptors of the deeper skin. Thus the microneedles supplement is supposed painless and reduces the infection and injuries. Researches from the past few years showed that microneedles have emerged as a novel carrier and considered to be effective for safe and improved delivery of the different drugs. Microneedles development is created a new pathway in the drug delivery field.
    [Show full text]
  • Nicorette Invisipatch 25 Mg/16 H Transdermal Patch
    SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Nicorette invisipatch 25 mg/16 h transdermal patch Nicorette invisipatch 15 mg/16 h transdermal patch Nicorette invisipatch 10 mg/16 h transdermal patch 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each transdermal patch contains nicotine 1.75 mg/cm2. Nicorette invisipatch 25 mg/16 h, of 22.5 cm2 size contains nicotine 39.37 mg and releases nicotine 25 mg /16 hours Nicorette invisipatch 15 mg/16 h, of 13.5 cm2 size contains nicotine 23.62 mg and releases nicotine 15 mg /16 hours Nicorette invisipatch 10 mg/16 h, of 9.0 cm2 size contains nicotine 15.75 mg and releases nicotine 10 mg /16 hours For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Transdermal patch Beige, semi-transparent, rectangular patch with rounded edges and light-brown “Nicorette” printing, is placed on an easily removable layer coated with aluminium and silicon and is formed by nicotine layer and adhesive acrylate layer. 4. CLINICAL PARTICULARS 4.1. Therapeutic indication Nicorette invisipatch is to be used for the treatment of tobacco dependence in adults by relief of nicotine withdrawal symptoms, including cravings, during a quit attempt. Permanent cessation of tobacco use is the eventual objective. Nicorette invisipatch is indicated in adults. Nicorette invisipatch should preferably be used in conjunction with a behavioral support program. 4.2. Posology and method of administration Posology Subjects should stop smoking completely during the course of treatment with Nicorette invisipatch. Administration of nicotine should be stopped immediately if any symptoms of overdose listed in Section 4.9 occur.
    [Show full text]
  • Transdermal Nicotine Maintenance Attenuates the Subjective And
    Neuropsychopharmacology (2004) 29, 991–1003 & 2004 Nature Publishing Group All rights reserved 0893-133X/04 $25.00 www.neuropsychopharmacology.org Transdermal Nicotine Maintenance Attenuates the Subjective and Reinforcing Effects of Intravenous Nicotine, but not Cocaine or Caffeine, in Cigarette-Smoking Stimulant Abusers 1 1 ,1,2 Bai-Fang X Sobel , Stacey C Sigmon and Roland R Griffiths* 1Department of Psychiatry and Behavioral Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA; 2Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA The effects of transdermal nicotine maintenance on the subjective, reinforcing, and cardiovascular effects of intravenously administered cocaine, caffeine, and nicotine were examined using double-blind procedures in nine volunteers with histories of using tobacco, caffeine, and cocaine. Each participant was exposed to two chronic drug maintenance phases (21 mg/day nicotine transdermal patch and placebo transdermal patch). Within each drug phase, the participant received intravenous injections of placebo, cocaine (15 and 30 mg/70 kg), caffeine (200 and 400 mg/70 kg), and nicotine (1.0 and 2.0 mg/70 kg) in mixed order across days. Subjective and cardiovascular data were collected before and repeatedly after drug or placebo injection. Reinforcing effects were also assessed after each injection with a Drug vs Money Multiple-Choice Form. Intravenous cocaine produced robust dose-related increases in subjective and reinforcing effects; these effects were not altered by nicotine maintenance. Intravenous caffeine produced elevations on several subjective ratings; nicotine maintenance did not affect these ratings. Under the placebo maintenance condition, intravenous nicotine produced robust dose-related subjective effects, with maximal increases similar to the high dose of cocaine; nicotine maintenance significantly decreased the subjective and reinforcing effects of intravenous nicotine.
    [Show full text]
  • Over-The-Counter Mail Order Program 1-866-768-8490 As a Superior
    Over-the-Counter Mail Order Program 1-866-768-8490 As a Superior value-added service, STAR+PLUS and STAR Health members can get $30 in items every 3 months (90 days). STAR members can get $25 in items every 3 months (90 days). No prescription is needed. To order, please call 1-866-768-8490. Have your Superior ID card ready when you call. Your order will be mailed to your home in 5-10 days. Please use these items only as directed. If you have questions about safe use of any of these items, talk to your doctor. Item Description Compare to: Price Item Description Compare to: Price Analgesics Eye Care 1 Ibuprofen 200mg tab Motrin IB $6 31 Tetrahydrozoline drops Visine $4 2 Naproxen sod 220mg tab Aleve $9 61 Lubricating eye drops Refresh Tears $7 3 Aspirin 325mg tab Bayer Aspirin $5 First Aid Creams/Ointments 4 Aspirin ec 325 mg tab Ecotrin $6 32 Calamine lotion Calamine Lotion $4 5 Aspirin ec 81 mg Halfprin $5 33 Hydrocortisone !5 cream Cort-Aid $4 6 Acetaminophen 500mg tab Tylenol Extra Str $6 34 Triple antibiotic ointment Neosporin $5 7 Mentholated ointment Ben Gay $6 60 Medicated lip balm Carmex $3 Antacids First Aid Supplies 8 Simethicone 80mg tab Mylanta Anti-Gas $6 35 Athletic bandage Ace Bandage $7 9 Calc carb 500mg chewable TUMS $6 36 Adhesive tape First-Aid Tape $3 10 Famotidine 10mg tab Pepcid AC $9 37 Band-aids Band-Aids $4 Antidiarrheals 38 Carbamide peroxide Debrox Drops $4 11 Loperamide 2mg cap Imodium $5 39 Gauze pads Gauze Pads $3 12 Bismuth mixture Pepto-Bismol $5 40 Cotton swab Q-Tips $4 Antifungals 41 Oral thermometer Thermometer
    [Show full text]
  • A Brief Review on Transdermal Patches
    Organic and Medicinal Chemistry International Journal ISSN 2474-7610 Review Article Organic & Medicinal Chem IJ Volume 7 Issue 2 - June 2018 Copyright © All rights are reserved by Nidhi Sharma DOI: 10.19080/OMCIJ.2018.07.555707 A Brief Review on Transdermal Patches Nidhi Sharma* HIMT College of Pharmacy, Greater Noida, India Submission: May 12, 2018; Published: June 05, 2018 *Corresponding author: Nidhi Sharma, HIMT College of Pharmacy, Greater Noida, India, Email: Abstract healingTransdermal to an injured drug area delivery of the system body. was An presentedadvantage toof overcome a transdermal the difficulties drug delivery of drug route delivery over especiallyother types oral of route. delivery A transdermal system such patch as oral, is a topical,medicated i.v., adhesive i.m., etc. ispatch that that the patchis placed provides on the askin controlled to deliver release a specific of the dose medication of medication into the through patient, the usually skin and through into the either bloodstream. a porous It membrane promotes covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive. The main disadvantage to transdermal delivery systems stems from the fact that the skin is a very effective barrier, as a result, only medications whose molecules are small can easily penetrate the skin, so it can be delivered by this method. This review article describes the overall introduction of transdermal patches including type of transdermal patches, method of preparation of transdermal
    [Show full text]
  • FDA Listing of Authorized Generics As of July 1, 2021
    FDA Listing of Authorized Generics as of July 1, 2021 Note: This list of authorized generic drugs (AGs) was created from a manual review of FDA’s database of annual reports submitted to the FDA since January 1, 1999 by sponsors of new drug applications (NDAs). Because the annual reports seldom indicate the date an AG initially entered the market, the column headed “Date Authorized Generic Entered Market” reflects the period covered by the annual report in which the AG was first reported. Subsequent marketing dates by the same firm or other firms are not included in this listing. As noted, in many cases FDA does not have information on whether the AG is still marketed and, if not still marketed, the date marketing ceased. Although attempts have been made to ensure that this list is as accurate as possible, given the volume of d ata reviewed and the possibility of database limitations or errors, users of this list are cautioned to independently verify the information on the list. We welcome comments on and suggested changes (e.g., additions and deletions) to the list, but the list may include only information that is included in an annual report. Please send suggested changes to the list, along with any supporting documentation to: [email protected] A B C D E F G H I J K L M N O P Q R S T U V X Y Z NDA Applicant Date Authorized Generic Proprietary Name Dosage Form Strength Name Entered the Market 1 ACANYA Gel 1.2% / 2.5% Bausch Health 07/2018 Americas, Inc.
    [Show full text]
  • Lna 2006 Profiles J.Qxp
    1 | Advertising Age | June 26, 2006 SpecialSpecial ReportReport:100 Profiles LEADING NATIONAL ADVERTISERSSupplement SUPPLEMENT June 26, 2006 100 LEADING NATIONAL ADVERTISERS Profiles of the top 100 U.S. marketers in this 51st annual ranking INSIDE TOP 100 RANKING COMPANY PROFILES SPONSORED BY The nation’s leading marketers Lead marketing personnel, ranked by U.S. advertising brands, agencies, agency expenditures for 2005. contacts, as well as advertising Includes data from TNS Media spending by media and brand, Intelligence and Ad Age’s sales, earnings and more for proprietary estimates of the country’s 100 largest unmeasured spending. PAGE 8 advertisers PAGE 10 This document, and information contained therein, is the copyrighted property of Crain Communications Inc. and The Ad Age Group (© Copyright 2006) and is for your personal, non-commercial use only. You may not reproduce, display on a website, distribute, sell or republish this document, or information contained therein, without prior written consent of The Ad Age Group. Are proud to connect you with the leading CMOs See all the interviews at adage.com/point LAUNCHING JUNE 28 © 2006 Crain Communications Inc. www.adage.com 3 | Advertising Age | June 26, 2006 Special Report 100 LEADING NATIONAL ADVERTISERS SUPPLEMENT ABOUT THIS PROFILE EDITION THE 51ST ANNUAL 100 Leading National the Top 100 ($40.13 billion) and for all measured spending in 18 national media, Advertisers Report crowned acquisition- advertisers ($122.79 billion) in the U.S. Yellow Pages Association contributed ladened Procter & Gamble Co. as the top U.S. ad spending by ad category: This spending in Yellow Pages and TNS Marx leader, passing previous kingpen General chart (Page 6) breaks out 18 measured Promotion Intelligence provided free- Motors Corp.
    [Show full text]
  • Lifescan Ethicon
    LouiseLouise MehrotraMehrotra ViceVice PresidentPresident InvestorInvestor RelationsRelations ““SafeSafe HarborHarbor”” StatementStatement This presentation may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the Company’s expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2006. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from the Company. The Company does not undertake to update any forward-looking statements as a result of new information or future events or developments. WilliamWilliam C.C. WeldonWeldon ChairmanChairman ofof thethe BoardBoard && ChiefChief ExecutiveExecutive OfficerOfficer TodayToday’’ss AgendaAgenda
    [Show full text]
  • Nicorette Invisipatch 25 Mg/16 H Transdermal Patch Nicorette Invisipatch 15 Mg/16 H Transdermal Patch Nicorette Invisipatch 10 Mg/16 H Transdermal Patch
    Package leaflet: Information for the user Nicorette invisipatch 25 mg/16 h transdermal patch Nicorette invisipatch 15 mg/16 h transdermal patch Nicorette invisipatch 10 mg/16 h transdermal patch (nicotine) Read all of this leaflet carefully before you start using this medicine because it contains important information for you. Always use this medicine exactly as described in this leaflet or as your doctor or pharmacist have told you. - Keep this leaflet. You may need to read it again. - Ask your pharmacist if you need more information or advice. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. - You must talk to a doctor if you have not been able to stop smoking after 6 months of treatment with Nicorette Invisipatch. What is in this leaflet: 1. What Nicorette invisipatch is and what it is used for 2. What you need to know before you use Nicorette invisipatch 3. How to use Nicorette invisipatch 4. Possible side effects 5 How to store Nicorette invisipatch 6. Contents of the pack and other information 1. What Nicorette invisipatch is and what it is used for Nicorette invisipatch is a medicinal product helping you to stop smoking. Nicorette invisipatch is used to treat tobacco dependence, to relieve cravings for smoking (nicotine) and nicotine withdrawal symptoms, which helps the motivated smokers to stop smoking. When you stop smoking and providing your body with nicotine from tobacco, you can experience unpleasant feelings called withdrawal symptoms. By using Nicorette invisipatch you can prevent or reduce these unpleasant feelings - by using Nicorette invisipatch patches you continue to provide your body with small amount of nicotine in its pure form, which does not bring about health risks associated with smoking.
    [Show full text]
  • Annual Report
    ANNUAL REPORT 2019 MARCH 2020 To Our Shareholders Alex Gorsky Chairman and Chief Executive Officer By just about every measure, Johnson & These are some of the many financial and Johnson’s 133rd year was extraordinary. strategic achievements that were made possible by the commitment of our more than • We delivered strong operational revenue and 132,000 Johnson & Johnson colleagues, who adjusted operational earnings growth* that passionately lead the way in improving the health exceeded the financial performance goals we and well-being of people around the world. set for the Company at the start of 2019. • We again made record investments in research and development (R&D)—more than $11 billion across our Pharmaceutical, Medical Devices Propelled by our people, products, and and Consumer businesses—as we maintained a purpose, we look forward to the future relentless pursuit of innovation to develop vital with great confidence and optimism scientific breakthroughs. as we remain committed to leading • We proudly launched new transformational across the spectrum of healthcare. medicines for untreated and treatment-resistant diseases, while gaining approvals for new uses of many of our medicines already in the market. Through proactive leadership across our enterprise, we navigated a constant surge • We deployed approximately $7 billion, of unique and complex challenges, spanning primarily in transactions that fortify our dynamic global issues, shifting political commitment to digital surgery for a more climates, industry and competitive headwinds, personalized and elevated standard of and an ongoing litigious environment. healthcare, and that enhance our position in consumer skin health. As we have experienced for 133 years, we • And our teams around the world continued can be sure that 2020 will present a new set of working to address pressing public health opportunities and challenges.
    [Show full text]